Key result
Oral anticoagulant therapy, including novel target-specific agents, carries ongoing risks of thromboembolic and bleeding complications that are expected to rise in the aging US population.
Answers are grounded in this paper and cite their sources.
The prevalence of thromboembolic and bleeding complications during oral anticoagulant therapy is expected to rise in the US due to an aging population, highlighting the need for awareness and use of risk prediction tools.
Oral anticoagulant therapy is used to prevent thromboembolism in patients with a variety of conditions, including nonvalvular atrial fibrillation and venous thrombosis, and in patients undergoing knee or hip replacement surgery. Excessive anticoagulation can lead to bleeding (e.g., intracranial hemorrhage), whereas inadequate anticoagulation can allow thromboembolism to occur. The successful use of oral anticoagulant therapy requires achieving a balance that minimizes both the risk for thromboembolism and the risk for bleeding. The introduction of several target-specific oral anticoagulants—dabigatran, rivaroxaban, and, most recently, apixaban—has been welcomed by both patients and health care providers because the routine laboratory monitoring required during warfarin use is generally not needed during the use of these agents. However, thromboembolic and bleeding complications can still occur during use of these novel agents.1 The prevalence of thromboembolic and bleeding complications during oral anticoagulant therapy in the United States is expected to rise in the coming years because the population is aging, many of the conditions for which therapy is used are age-related, and use of these drugs to manage these conditions is widespread.2–4 Although tools are available to predict the risk for thromboembolism and bleeding in patients requiring oral anticoagulant therapy, clinicians’ awareness of these risks and use of these tools may be inadequate.5–10
No takes yet. Share an insight, caveat, or question.
Edith A. Nutescu (2013) conducted a review in Thromboembolism and bleeding. Oral anticoagulant therapy was evaluated. Oral anticoagulant therapy, including novel target-specific agents, carries ongoing risks of thromboembolic and bleeding complications that are expected to rise in the aging US population.
Synapse has enriched 10 related papers. Consider them for comparative context: